Compare Quest Diagnostics Inc (DGX) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

First Citizens BancShares (FCNCA) trades at $2,106.06, up 0.64% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $44.86 exceeding expectations by 13.4%. Recent developments include expansion of commercial banking capabilities and the planned retirement of the Silicon Valley Bank brand name in Q4 2026. The company maintains solid profitability with a 24.35% net income margin and 10.5% ROE, supported by $9.25B in revenue for 2025.

FCNCA presents a mixed investment case with strong fundamentals but cautious analyst sentiment. While valuation appears reasonable at 11.89 P/E and 1.18 P/B ratios, the majority of analysts (81.82%) maintain Hold ratings. Key opportunities include continued earnings momentum and strategic brand alignment, while risks involve margin pressure and credit exposure in the tech sector. The consensus price target of $2,320 suggests modest upside potential from current levels.